Skip to main content

PAPEL DE LAS PROTEINAS RELACIONADAS CON FH EN LA REGULACION DEL COMPLEMENTO Y NUEVOS MODELOS DE RATON DE DESREGULACION DEL COMPLEMENTO

PID2019-104912RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Detection of genetic rearrangements in the regulators of complement activation RCA cluster by high-throughput sequencing and MLPA

  • García-Fernández, Jesús
  • Vilches, Susana
  • Olavarrieta, Leticia
  • Pérez Pérez, J.
  • Rodríguez de Córdoba, Santiago
20 p.-6 fig.-3 tab., The regulators of complement activation (RCA) gene cluster in 1q31-1q32 includes most of the genes encoding complement regulatory proteins. Genetic variability in the RCA gene cluster frequently involve copy number variations (CNVs), a type of chromosome structural variation causing alterations in the number of copies of specific regions of DNA. CNVs in the RCA gene cluster often relate with gene rearrangements that result in the generation of novel genes, carrying internal duplications or deletions, and hybrid genes, resulting from the fusion or exchange of genetic material between two different genes. These gene rearrangements are strongly associated with a number of rare and common diseases characterized by complement dysregulation. Identification of CNVs in the RCA gene cluster is critical in the molecular diagnostic of these diseases. It can be done by bioinformatics analysis of DNA sequence data generated by massive parallel sequencing techniques (NGS, next generation sequencing) but often requires special techniques like multiplex ligation-dependent probe amplification (MLPA). This is because the currently used massive parallel DNA sequencing approaches do not easily identify all the structural variations in the RCA gene cluster. We will describe here how to use the MLPA assays and two computational tools to analyze NGS data, NextGENe and ONCOCNV, to detect CNVs and gene rearrangements in the RCA gene cluster., SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R, PID2019-104912RB-I00, RTC-2016-4635-1 and the Autonomous Region of Madrid (S2017/BMD-3673). Secugen has received a soft loan from the Spanish “Ministerio de Economía y Competitividad” Retos Program RTC-2016-4635-1 cofinanced by FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Functional characterization of 105 Factor H variants associated with HUS:lessons for variant classification

  • Martín Merinero, Héctor
  • Zhang, Yuzhou
  • Arjona, Emilia
  • Del Ángel, Guillermo
  • Goodfellow, Renee
  • Gomez-Rubio, Elena
  • Ji, Rui-Ru
  • Michelena, Malkoa
  • Smith, Richard
  • Rodríguez de Córdoba, Santiago
36 p.-3 fig.-3 tab., Atypical hemolytic uremic syndrome (aHUS) is alife-threatening thrombotic microangiopathy that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is caused by complement dysregulationdue topathogenic variants in genes that encode complement components and regulators. Amongst these genes, the Factor H (FH) gene, CFH, presents with the highest frequency (15-20%) of variantsand is associated with the poorest prognosis. Correct classification of CFH variants as pathogenic or benign is essential to clinical care but remainschallenging owing to the dearth of functional studies. As a result, significant numbers of variants are reported as variants of uncertain significance. Toaddress this knowledge gap, we expressed and functionally characterized105 aHUS-associated FH variants. All FH variants were categorized as pathogenic or benign, and for each,we fully documented the nature of the pathogenicity. Twenty-sixpreviously characterizedFH variantswere used as controls to validate and confirm the robustness of the functional assays used. Of the remaining 79 uncharacterized variants, only 29 (36.7%)alter FH in vitroexpression or function and are therefore proposed to be pathogenic. We show that rarityin control databases isnot informative for variant classification,andwe identifyimportant limitations in applying prediction algorithms toFH variants. Based on structural and functional data, we suggest ways to circumvent these difficultiesand thereby improve variant classification.Our work highlights the need for functional assays to interpret FH variants accuratelyif clinical care of patients with aHUS is to be individualized and optimized., SRdC was supported by grants from the Spanish Ministerio de Economía y Competitividad-FEDER (PID2019-104912RB-I00) and Autonomous Region of Madrid (S2017/BMD-3673). RJHS was supported, in part, by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 110023). Conception, design, data collection and analysis, as well as writing of the manuscript, was performed with support from Alexion Pharmaceuticals, Inc. Editorial support, funded by Alexion Pharmaceuticals Inc., Boston, MA, was provided by Oxford PharmaGenesis, Oxford, UK., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gain-of-function mutations R249C and S250C in complement C2 protein increase C3 deposition in the presence of C-reactive protein

  • Urban, Aleksandra
  • Kowalska, Daria
  • Stasiłojć, Grzegorz
  • Kuźniewska, Alicja
  • Skrobi´nska, Anna
  • Arjona, Emilia
  • Castellote Alonso, Eugenia
  • Fenollosa, María Ángeles
  • Jongerius, Ilse
  • Spaapen, Robbert
  • Satchell, Simon
  • Thiel, Marcel
  • Oldziej, Stanislaw
  • Rodríguez de Córdoba, Santiago
  • Okrój, Marcin
8 p.-4 fig., The impairment of the alternative complement pathway contributes to rare kidney diseases such as atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). We recently described an aHUS patient carrying an exceptional gain-of-function (GoF) mutation (S250C) in the classical complement pathway component C2 leading to the formation of hyperactive classical convertases. We now report the identification of the same mutation and another C2 GoF mutation R249C in two other patients with a glomerulopathy of uncertain etiology. Both mutations stabilize the classical C3 convertases by a similar mechanism. The presence of R249C and S250C variants in serum increases complement-dependent cytotoxicity (CDC) in antibody-sensitized human cells and elevates deposition of C3 on ELISA plates coated with C-reactive protein (CRP), as well as on the surface of glomerular endothelial cells. Our data justify the inclusion of classical pathway genes in the genetic analysis of patients suspected of complement-driven renal disorders. Also, we point out CRP as a potential antibody-independent trigger capable of driving excessive complement activation in carriers of the GoF mutations in complement C2., The project was funded by National Science Centre Poland grant nos. 2015/18/M/NZ6/00334 and 2018/29/N/NZ6/01413. SRC was supported by grants from the Spanish Ministerio de Economía y Competitividad-FEDER (PID2019-104912RB-I00) and Autonomous Region of Madrid (S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor

  • Fernández, Francisco J.
  • Santos-López, Jorge
  • Martínez-Barricarte, Rubén
  • Querol-García, Javier
  • Martín Merinero, Héctor
  • Navas-Yuste, Sergio
  • Savko, Martin
  • Shepard, William E.
  • Rodríguez de Córdoba, Santiago
  • Vega, María Cristina
16 p.-9 fig., Complement activation on cell surfaces leads to the massive deposition of C3b, iC3b, and C3dg, the main complement opsonins. Recognition of iC3b by complement receptor type 3 (CR3) fosters pathogen opsonophagocytosis by macrophages and the stimulation of adaptive immunity by complement-opsonized antigens. Here, we present the crystallographic structure of the complex between human iC3b and the von Willebrand A inserted domain of the α chain of CR3 (αI). The crystal contains two composite interfaces for CR3 αI, encompassing distinct sets of contiguous macroglobulin (MG) domains on the C3c moiety, MG1-MG2 and MG6-MG7 domains. These composite binding sites define two iC3b-CR3 αI complexes characterized by specific rearrangements of the two semi-independent modules, C3c moiety and TED domain. Furthermore, we show the structure of iC3b in a physiologically-relevant extended conformation. Based on previously available data and novel insights reported herein, we propose an integrative model that reconciles conflicting facts about iC3b structure and function and explains the molecular basis for iC3b selective recognition by CR3 on opsonized surfaces., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (to M.C.V.) and PID2019-104912RB-I00 (to S.R.C.), and Spanish Ministerio de Economía y Competitividad-FEDER grants SAF2015-72961-EXP (to M.C.V.) and SAF2015-66287-R (to S.R.C.). It was also funded by Grant S2017/BMD-3673 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to S.R.C. and M.C.V.), and the CSIC Special Intramural Grant PIE-201620E064 (to M.C.V.). It was additionally supported by the Network of Excellence Complement in Health and Disease (SAF2016-81876-REDT). SRC was also supported by the CIBER de Enfermedades Raras. JSL acknowledges the support of the PhD program in Molecular Biosciences of the Universidad Autónoma de Madrid (UAM) and the Ministry of Education, Culture and Sports of Spain (FPU Grant 17/06090). SNY acknowledges the support of the PhD program in Biochemistry, Molecular Biology and Biomedicine of the Universidad Complutense de Madrid (UCM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Factor H-related protein 1 drives disease susceptibility and prognosis in C3 glomerulopathy

  • Márquez-Tirado, Bárbara
  • Gutiérrez-Tenorio, Josué
  • Tortajada, Agustín
  • Lucientes, Laura
  • Caravaca-Fontán, Fernando
  • Malik, T. H.
  • Roldán Montero, Raquel
  • Elías, Sandra
  • Saiz Gonzalez, Ana
  • Fernández-Juárez, Gema
  • Sánchez-Corral, Pilar
  • Pickering, Matthew C.
  • Praga, Manuel
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
17 p.-8 fig., Background: C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization domains are prototypical of C3G, although the underlying pathogenic mechanism is unclear., Methods: Using in vitro and in vivo assays, we performed extensive characterization of an FHR-1 mutant with a duplicated dimerization domain. To assess the FHR-1 mutant's association with disease susceptibility and renal prognosis, we also analyzed CFHR1 copy number variations and FHR-1 plasma levels in two Spanish C3G cohorts and in a control population., Results: Duplication of the dimerization domain conferred FHR-1 with an increased capacity to interact with C3-opsonized surfaces, which resulted in an excessive activation of the alternative pathway. This activation does not involve C3b binding competition with factor H. These findings support a scenario in which mutant FHR-1 binds to C3-activated fragments and recruits native C3 and C3b; this leads to formation of alternative pathway C3 convertases, which increases deposition of C3b molecules, overcoming FH regulation. This suggests that a balanced FHR-1/FH ratio is crucial to control complement amplification on opsonized surfaces. Consistent with this conceptual framework, we show that the genetic deficiency of FHR-1 or decreased FHR-1 in plasma confers protection against developing C3G and associates with better renal outcome., Conclusions: Our findings explain how FHR-1 mutants with duplicated dimerization domains result in predisposition to C3G. They also provide a pathogenic mechanism that may be shared by other diseases, such as IgA nephropathy or age-related macular degeneration, and identify FHR-1 as a potential novel therapeutic target in C3G., E. Goicoechea de Jorge is supported by Ministerio de Ciencia e Innovación grant RTI2018-095955-B-100 and the European Union’s Horizon 2020 Framework Programme grant 899163. J. Gutiérrez-Tenorio is supported by Ministerio de Ciencia e Innovación grant BES-2015-073833. L. Lucientes Continente is supported by the Autonomous Region of Madrid grant S2017/BMD-3673. G. Fernández-Juarez, P. Sánchez-Corral, B. Márquez-Tirado, and M. Praga are supported by the Instituto de Salud Carlos III and the European Union’s European Regional Development Fund grants PI19/01695, PI19/00970, and PI19/01624, respectively. M.C. Pickering is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). S. Rodríguez de Córdoba is supported by the Ministerio de Economía y Competitividad grant PID2019-104912RB-100 and Autonomous Region of Madrid grant S2017/BMD-3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases

  • Rodríguez de Córdoba, Santiago
20 p.-7 fig.-1 tab., The implementation of next-generation sequencing technologies has provided a sharp picture of the genetic variability in the components and regulators of the alternative pathway (AP) of the complement system and has revealed the association of many AP variants with different rare and common diseases. An important finding that has emerged from these analyses is that each of these complement-related diseases associate with genetic variants altering specific aspects of the activation and regulation of the AP. These genotype–phenotype correlations have provided valuable insights into their pathogenic mechanisms with important diagnostic and therapeutic implications. While genetic variants in coding regions and structural variants are reasonably well characterized and occasionally have been instrumental to uncover unknown features of the complement proteins, data about complement expressed quantitative trait loci are still very limited. A crucial task for future studies will be to identify these quantitative variations and to determine their impact in the overall activity of the AP. This is fundamental as it is now clear that the consequences of genetic variants in the AP are additive and that susceptibility or resistance to disease is the result of specific combinations of genetic variants in different complement components and regulators (“complotypes”)., SRdC was supported by grants from the Spanish Ministerio de Economía y Competitividad-FEDER (PID2019-104912RB-I00) and Autonomous Region of Madrid (S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

  • Caravaca-Fontán, Fernando
  • Rivero, Marta
  • Cavero, Teresa
  • Díaz-Encarnación, Montserrat M.
  • Cabello-Chaves, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
10 p.-4 fig.-2 tab. 1 graph. abst., Background: C3 glomerulopathy is a rare and heterogeneous complement-driven disease. It is often challenging to accurately predict in clinical practice the individual kidney prognosis at baseline. We herein sought to develop and validate a prognostic nomogram to predict long-term kidney survival., Methods: We conducted a retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. The dataset was randomly divided into a training group (n = 87) and a validation group (n = 28). The least absolute shrinkage and selection operator (LASSO) regression was used to screen the main predictors of kidney outcome and to build the nomogram. The accuracy of the nomogram was assessed by discrimination and risk calibration in the training and validation sets., Results: The study group comprised 115 patients, of whom 46 (40%) reached kidney failure in a median follow-up of 49 months (range 24–112). No significant differences were observed in baseline estimated glomerular filtration rate (eGFR), proteinuria or total chronicity score of kidney biopsies, between patients in the training versus those in the validation set. The selected variables by LASSO were eGFR, proteinuria and total chronicity score. Based on a Cox model, a nomogram was developed for the prediction of kidney survival at 1, 2, 5 and 10 years from diagnosis. The C-index of the nomogram was 0.860 (95% confidence interval 0.834–0.887) and calibration plots showed optimal agreement between predicted and observed outcomes., Conclusions: We constructed and validated a practical nomogram with good discrimination and calibration to predict the risk of kidney failure in C3 glomerulopathy patients at 1, 2, 5 and 10 years., Work on this study was supported by the Instituto de Salud Carlos III / Fondo Europeo de Desarrollo Regional (ISCIII/FEDER; grants PI16/01685 and PI19/1624) and Red de Investigación Renal (RD12/0021/0029; to M.P.) and the Autonomous Region of Madrid (S2017/BMD-3673; to M.P.). S.R.d.C. is supported by the Ministerio de Economia y Competitividad (grant PID2019-104912RB-I00) and the Autonomous Region of Madrid (grant S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Substitutions at position 263 within the von Willebrand factor type A domain determine the functionality of complement C2 protein

  • Kuźniewska, Alicja
  • Thiel, Marcel
  • Kowalska, Daria
  • Felberg, Anna
  • Szynkowski, Patryk
  • Oldziej, Stanislaw
  • Arjona, Emilia
  • Jongerius, Ilse
  • Rodríguez de Córdoba, Santiago
  • Okrój, Marcin
  • Urban, Aleksandra
8 p.-4 fig., The complement system is one of the first defense lines protecting from invading pathogens. However, it may turn offensive to the body’s own cells and tissues when deregulated by the presence of rare genetic variants that impair physiological regulation and/or provoke abnormal activity of key enzymatic components. Factor B and complement C2 are examples of paralogs engaged in the alternative and classical/lectin complement pathway, respectively. Pathogenic mutations in the von Willebrand factor A domain (vWA) of FB have been known for years. Despite substantial homology between two proteins and the demonstration that certain substitutions in FB translated to C2 result in analogous phenotype, there was a limited number of reports on pathogenic C2 variants in patients. Recently, we studied a cohort of patients suffering from rare kidney diseases and confirmed the existence of two gain-of-function and three loss-of-function mutations within the C2 gene sequences coding for the vWA domain (amino acids 254-452) or nearly located unstructured region (243-253) of C2 protein. Herein, we report the functional consequences of amino acid substitution of glutamine at position 263. The p.Q263G variant resulted in the gain-of-function phenotype, similarly to a homologous mutation p.D279G in FB. Conversely, the p.Q263P variant found in a patient with C3 glomerulopathy resulted in the loss of C2 function. Our results confirm that the N-terminal part of the vWA domain is a hot spot crucial for the complement C2 function, This study was supported by National Science Centre Poland grants no. 2015/18/M/NZ6/00334 (to MO), 2018/29/N/NZ6/01413, and 2019/32/T/NZ6/00328 (both to AU), and UGrants Start 2022 no. 1220/97/2022 from the University of Gdańsk (to AK). SRdC was supported by grants from the Spanish Ministerio de Economía y Competitividad-FEDER (PID2019-104912RB-I00) and Autonomous Region of Madrid (S2017/BMD-3673, S2022/BMD-7278)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy

  • Caravaca-Fontán, Fernando
  • Cavero, Teresa
  • Díaz-Encarnación, Montserrat M.
  • Cabello-Chaves, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Rivas, Begoña
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
14 p.-4 fig.-3 tab., Background C3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease., Methods This was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m2, proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria., Results One hundred and fifteen patients with a median age of 30 years (interquartile range 19–50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73 m2. The median eGFR slope of patients who reached kidney failure was −6.5 ml/min per 1.73 m2 per year (interquartile range −1.6 to −17). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (≥5 ml/min per 1.73 m2 per year), slower (<5 ml/min per 1.73 m2 per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure., Conclusions Kidney survival is significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure., Work in this study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and PI19/1624, and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to MP), the Autonomous Region of Madrid (S2017/BMD-3673) (to MP). SRdeC is supported by Ministerio de Economia y Competitividad grant PID2019-104912RB-I00 y Autonomous Region of Madrid grant S2017/BMD-3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The structure of Leptospira interrogans GAPDH sheds light into an immunoevasion factor that can target the anaphylatoxin C5a of innate immunity

  • Navas-Yuste, Sergio
  • De la Paz-García, Karla
  • Querol-García, Javier
  • Gómez, Sara
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
15 p.-7 fig.-4 tab., Leptospirosis is a neglected worldwide zoonosis involving farm animals and domestic pets caused by the Gram-negative spirochete Leptospira interrogans.This bacterium deploys a variety of immune evasive mechanisms, some of them targeted at the complement system of the host’s innate immunity. In this work, we have solved the X-ray crystallographic structure of L. interrogans glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to 2.37-Å resolution, a glycolytic enzyme that has been shown to exhibit moonlighting functions that potentiate infectivity and immune evasion in various pathogenic organisms.Besides, we have characterized the enzyme’s kinetic parameters toward the cognate substrates and have proven that the two natural products anacardic acid and curcumin are able to inhibit L. interrogans GAPDH at micromolar concentration through a noncompetitive inhibition modality. Furthermore, we have established that L. interrogans GAPDH can interact with the anaphylatoxin C5a of human innate immunity in vitro using bio-layer interferometry and a short-range cross-linking reagent that tethers free thiol groups in protein complexes. To shed light into the interaction between L. interrogans GAPDH and C5a, we have also carried out cross-link guided protein-protein docking. These results suggest that L. interrogans could be placed in the growing list of bacterial pathogens that exploit glycolytic enzymes as extracellular immune evasive factors. Analysis of the docking results indicates a low affinity interaction that is consistent with previous evidence, including known binding modes of other a-helical proteins with GAPDH. These findings allow us to propose L. interrogans GAPDH as a potential immune evasive factor targeting the complement system., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-B-I00 (to MCV) and PID2019-104912RB-I00 (to SRdC); and the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00. It was also funded by Grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to SRdC and MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). SRdC was also supported by the CIBER de Enfermedades Raras. KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome

  • Huerta, Ana
  • Arjona, Emilia
  • Portoles, Jose
  • Lopez-Sanchez, Paula
  • Cavero, Teresa
  • Fernandez-Cusicanqui, Jeanette
  • Blasco, Miquel
  • Cabello, Virginia
  • Calvo, Natividad
  • Díaz-Encarnación, Montserrat M.
  • Herrero-Goñi, Maria
  • Aguirre, Mireia
  • Elías, Sandra
  • Alcaide, Maria Paz
  • Ramos, Natalia
  • Sellares, Joana
  • Rodríguez de Córdoba, Santiago
5 p.-1 fig.-1 tab., This project was funded by the Instituto de Salud Carlos III: REDinREN (RD016/009/009) and Instituto de Investigacion Puerta de Hierro-Segovia Arana (IDIPHISA) to AH and by grants from the Spanish Ministerio de Economía y Competitividad–FEDER (European Regional Development Fund) (PID2019-104912RB-I00) and the Autonomous Region of Madrid (S2017/BMD-3673 and S2022/BMD-7278) to SRdC. TC was supported by grant from National Health Institute Carlos III (RETIC ISCIII RD21/0005. RICORS),, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Thrombotic microangiopathy in patients with malignant hypertension

  • Cavero, Teresa
  • Auñón, Pilar
  • Caravaca-Fontán, Fernando
  • Trujillo, Hernando
  • Arjona, Emilia
  • Morales, Enrique
  • Guillén, Elena
  • Blasco, Miquel
  • Rabasco, Cristina
  • Espinosa, Mario
  • Blanco, Marta
  • Rodríguez-Magariños, Catuxa
  • Cao, Mercedes
  • Ávila, Ana
  • Huerta, Ana
  • Rubio, Esther
  • Cabello-Chaves, Virginia
  • Barros, Xoana
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
  • Praga, Manuel
10 p.-4 fig.-4 tab., Background: Thrombotic microangiopathy (TMA) is a complication of malignant hypertension (mHTN) attributed to high blood pressure (BP). However, no studies have investigated in patients with mHTN of different aetiologies whether the presence of TMA is associated with specific causes of mHTN., Methods: We investigated the presence of TMA (microangiopathic haemolytic anaemia and thrombocytopenia) in a large and well-characterized cohort of 199 patients with mHTN of different aetiologies [primary HTN 44%, glomerular diseases 16.6%, primary atypical haemolytic uraemic syndrome (aHUS) 13.1%, renovascular HTN 9.5%, drug-related HTN 7%, systemic diseases 5.5%, endocrine diseases 4.5%]. Outcomes of the study were kidney recovery and kidney failure., Results: Patients with TMA [40 cases (20.1%)] were younger, were more likely female and had lower BP levels and worse kidney function at presentation. Their underlying diseases were primary aHUS (60%), drug-related mHTN (15%), glomerular diseases [all of them immunoglobulin A nephropathy (IgAN); 10%], systemic diseases (10%) and primary HTN (5%). The presence of TMA was 92.3% in primary aHUS, 42.9% in drug-related HTN, 36.4% in systemic diseases, 12.1% in glomerular diseases and 2.3% in primary HTN. No patient with renovascular HTN or mHTN caused by endocrine diseases developed TMA, despite BP levels as high as patients with TMA. A higher proportion of TMA patients developed kidney failure as compared with patients without TMA (56.4% versus 38.9%, respectively)., Conclusions: The presence of TMA in patients with mHTN should guide the diagnosis towards primary aHUS, drug-related mHTN, some systemic diseases and IgAN, while it is exceptional in other causes of mHTN., Work in this study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional [ISCIII/FEDER;grants PI13/02502 and PICI14/00350 (to M.P.) and PI16/01685 and PI19/01624 (to M.P. and T.C.)]; the Spanish Ministerio de Economía y Competitividad/FEDER [SAF2015-66287-R and PID2019-104912RB-I00 (to S.R.d.C.)]; the Spanish ‘Ministerio de Ciencia Innovación y Universidades’ [RTI2018-095955-B-100 (to E.G.J.)]; the Autonomous Region of Madrid [S2017/BMD-3673 (to E.G.J., S.R.d.C. and M.P.)] and Red de Investigación Renal [RD12/0021/0029 (to M.P.)]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel immunochromatographic test for rapid detection of anti-factor H autoantibodies with an assessment of its clinical relevance

  • Rodríguez de Córdoba, Santiago
  • Reparaz, Andrea
  • Sánchez, Daniel
  • Pinto, Sheila
  • López, Lucia Juana
  • Martín Merinero, Héctor
  • Calvete, Iria
  • Pérez-Pérez, Julián
  • Jellison, Sidney S.
  • Zhang, Yuzhou
  • Smith, Richard
  • Moreno, Inmaculada
  • Domínguez, Mercedes
19 p.-8 fig.-5 tab., Factor H (FH) is a crucial complement regulator that prevents complement-mediated injury to healthy cells and tissues. This regulatory function can be disrupted by Factor H autoantibodies (FHAA), which then leads to diseases such as atypical hemolytic uremic syndrome (aHUS) and C3 Glomerulopathy (C3G). In pediatric aHUS, the FHAA incidence is ~10-15%, although in the Indian population, it rises to ~50%. The specific regions of FH targeted by FHAAs correlate with the pathogenic mechanism of the associated disease. In aHUS, FHAAs target the C-terminus, thereby impacting FH ability to recognize cell surfaces. In C3G, in contrast, FHAAs often target the N-terminus, generating an acquired functional FH deficiency. Detection and monitoring FHAAs are decisive for effectively treating patients. Current FHAA analysis normally identify free FHAAs that bind surface-bound FH using ELISA techniques. These methods require well-equipped laboratories and qualified staff, and do not measure FH-FHAA complexes, which can make it difficult to correlate titers with clinical outcomes. The visually-based immunochromatographic test (ICT) described herein allows for quick detection and quantification of IgG and IgM FH-FHAA complexes in human EDTA-plasma or serum. This ICT offers improved detection of FHAAs compared to ELISA as demonstrated by cases where the ICT identifies FH-FHAA complexes in samples that tested negative with the free FHAA ELISA. Importantly, the ICT indirectly informs on the amount of FH that is complexed with FHAAs, thus assessing the significance of the FHAA in disrupting the regulatory function of FH. Overall, this novel assay offers a simple, fast, cost-effective, and, likely, more clinically relevant alternative for diagnosing FHAAs in at-risk populations., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SR was supported by grants from the Spanish Ministerio de Economía y Competitividad-FEDER (PID2019-104912RB-I00) and Autonomous Region of Madrid (S2022/BMD-7278). RS was supported in part by a grant from the National Institutes of Health (R01 DK110023)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Functional and structural characterization of mouse Factor H-related B protein unveils a novel dimerization domain shared by FHR-B and FH

  • Martín-Ambrosio, Adrián
  • González-Sanz, Silvia
  • Márquez Tirado, Bárbara
  • Juana-López, Lucía
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
  • Martín Merinero, Héctor
18 p.-14 fig., Factor H-related proteins (FHRs) are found in mice, but their equivalence to human FHRs remains uncertain. This study identifies three FHRs in mouse plasma (FHR-B, FHR-C, and FHR-E) and focuses on characterizing FHR-B. Using purified plasma proteins and recombinant mutants, FHR-B was found to form dimers and bind strongly to C3, C3b, iC3b, and C3dg. It also competes with mouse Factor H (mFH) for binding to C3b-coated surfaces and disrupts mFH regulation in hemolysis assays with sheep and guinea pig erythrocytes. These functions are localized to the C-terminal region and are dependent on FHR-B dimerization. Dimerization occurs through the N-terminal region (SCR1-3), which differs from mFH SCR5-7 by only four amino acids and also shares significant homology with human FHR-3 and human FH SCR5-7. In contrast to FHR-1, AUC experiments indicate that FHR-B dimerization is pH-sensitive, reversible and that the monomers in the dimer present the same head to tail orientation. Mutant analyses revealed that mFH SCR5-7 also forms dimers, but less efficiently than FHR-B. Notably, substituting FHR-B Tyr162 (a key residue homologous to the disease-associated Tyr402 in human FH) for His reduces dimerization. We also found that a recombinant FHR-B with a duplicated dimerization domain formed stable dimers but lacked functional activity. Overall, FHR-B shows structural and functional similarities with various human FHRs, suggesting convergent evolution between mouse and human FHRs. Furthermore, this study reveals a novel dimerization domain shared by FHR-B and mouse FH and illustrates the importance of dimerization and monomer orientation in FHRs activity. It also underlines notable differences between human and mice FHRs that should be further explored before modeling FHR-associated human diseases in mice. Copyright © 2025 Martín-Ambrosio Doménech, González Sanz, Márquez Tirado, Juana-López, Goicoechea de Jorge, Rodríguez de Córdoba and Martín Merinero., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SR is supported by Spanish “Ministerio de Ciencia, Innovación y Universidades” grant PID2019-104912RB-I00 and RED2022-134750-T, and Autonomous Region of Madrid grant S2022/BMD-7278. EG is supported by “Ministerio de Ciencia, Innovación y Universidades” grant PID2022-138819OB-I00, the European Union’s Horizon 2020 Framework Programme grant 899163 and the Autonomous Region of Madrid grant P2022/BMD-7278., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Cabello, Virginia
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Barros, Xoana|||0000-0001-9690-9769
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez-Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia|||0000-0001-9857-793X
  • Sánchez de la Nieta, María Dolores
  • Rodríguez García, Eva
  • Rivas, Begoña|||0000-0002-5886-9943
  • Melgosa, Marta|||0000-0001-6236-414X
  • Huerta, Ana|||0000-0003-3342-7628
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • De Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir|||0000-0001-7039-4701
  • López-Rubio, Maria Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, Luis
  • Da Silva, Iara
  • Titos, Juana Alonso
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874
  • Goicoechea de Jorge, Elena|||0000-0002-4978-2483
  • Praga, Manuel|||0000-0001-9270-1071
C3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease. This was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m 2, proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria. One hundred and fifteen patients with a median age of 30 years (interquartile range 19-50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73 m 2. The median eGFR slope of patients who reached kidney failure was -6.5 ml/min per 1.73 m 2 per year (interquartile range -1.6 to -17). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (≥5 ml/min per 1.73 m 2 per year), slower (<5 ml/min per 1.73 m 2 per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure. Kidney survival is significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome

  • Huerta, Ana|||0000-0003-3342-7628
  • Arjona, Emilia|||0000-0002-0753-3657
  • Portoles, José
  • López Sánchez, Paula|||0000-0002-4332-5759
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Fernandez-Cusicanqui, Jeanette
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Cabello, Virginia
  • Calvo, Natividad
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Herrero-Goñi, Maria
  • Aguirre, Mireia
  • Elías, Sandra
  • Alcaide, María Paz
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Sellares, Joana|||0000-0002-0394-8011
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874